866-997-4948(US-Canada Toll Free)

Ovarian Cancer-Pipeline Insights, 2016

Published By :


Published Date : Jul 2016

Category :

Ovarian Cancer

No. of Pages : 260 Pages

DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries. It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK. The report provides the in-depth analysis of the pipeline assets across the Ovarian Cancer. The Report gives insights on 225+ products. It also includes around 185+ companies which are active in this field. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Ovarian Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Ovarian Cancer. These days companies are focusing on the Targeted Therapy for cancer. Roches Pertuzumab, Merck Avelumab and Morphoteks Farletuzumab is the monoclonal antibody in Phase III stage competing against the other small molecules in development. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. These are in preregistration stage of development.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
The new report, provides a Ovarian Cancer Landscape across the globe
The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
Coverage of the Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide company profiling
Pipeline products coverage based on various stages of development from NDA filings to discovery.
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Table of Contents

Ovarian Cancer Overview
Signs and symptoms
Pipeline Therapeutics
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Consulting Services
About DelveInsight
Contact Us

List of Tables

1:Number of Products Under Development for Ovarian cancer, 2016
Table 2: Number of Products under Development by Companies, 2016
Table 3: Last Stage Products (Phase III and Filed),2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I), 2016
Table 6: Pre-Clinical and Discovery Products, 2016
Table 7: Assessment by Monotherapy Products, 2016
Table 8: Assessment by Combination Products, 2016
Table 9:Assessment by Route Of Administration, 2016
Table 10:Assessment by Stage and Route Of Administration, 2016
Table 11:Assessment by Molecule Type, 2016
Table 12:Assessment by Stage and Molecule Type, 2016
Table 13: Dormant Products, 2016
Table 14:Discontinued Products, 2016

List of Figures
Figure 1: Number of Products under Development for Ovarian cancer, 2016
Figure 2:Last Stage Products (Phase III), 2016
Figure 3: Mid Stage Products (Phase II), 2016
Figure 4:Early Stage Products (Phase III), 2016
Figure 5: Discovery and Pre-clinical Stage Products, 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Combination Products, 2016
Figure 8: Assessment by Route of Administration, 2016
Figure 9: Assessment by Stage and Route of Administration, 2016
Figure 10: Assessment by Molecule Type, 2016
Figure 11:Assessment by Stage and Molecule Type, 2016
Figure 12:Dormant Products, 2016
Figure 13:Discontinued Products, 2016

List of Table


Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *